OPKO Health, Inc. Research and Development in Process
OPKO Health, Inc. (OPK) reported Research and Development in Process of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2017-03-01
- OPKO Health, Inc. research and development in process for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- OPKO Health, Inc. research and development in process for the quarter ending 2015-09-30 was $0.00.
- OPKO Health, Inc. research and development in process for the quarter ending 2015-06-30 was $0.00, a 100.00% decline year-over-year.
- OPKO Health, Inc. research and development in process for the quarter ending 2014-12-31 was $2.00M.
- OPKO Health, Inc. research and development in process for fiscal 2016 was $0.00.
- OPKO Health, Inc. research and development in process for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- OPKO Health, Inc. research and development in process for fiscal 2014 was $12.05M.
- OPKO Health, Inc. research and development in process for fiscal 2013 was $0.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-01 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $0.00 derived: sum of 2 quarters · filed 2017-03-01 | $0.00 derived: sum of 3 quarters · filed 2017-03-01 | $0.00 10-K · filed 2017-03-01 |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $0.00 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $0.00 10-Q · filed 2015-08-05 | $0.00 10-Q · filed 2015-08-05 | ||
| 2014-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $2.00M derived: sum of 2 quarters · filed 2017-03-01 | $12.05M derived: sum of 3 quarters · filed 2017-03-01 | $12.05M 10-K · filed 2017-03-01 |
| 2014-09-30 | $0.00 10-Q · filed 2015-11-09 | $10.05M derived: sum of 2 quarters · filed 2015-11-09 | $10.05M 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $10.05M 10-Q · filed 2015-08-05 | $10.05M 10-Q · filed 2015-08-05 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | $0.00 10-K · filed 2016-02-29 |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-07 | $0.00 derived: sum of 2 quarters · filed 2014-11-07 | $0.00 10-Q · filed 2014-11-07 | |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-11 | $0.00 10-Q · filed 2014-08-11 | ||
| 2012-12-31 | $0.00 10-K · filed 2015-02-27 | |||
| 2009-12-31 | $2.00M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |